GlassScriptPhysician profile
Gregory W Smith
NPI 1457565913
$4,387.20
in general payments reported to CMS, 2019-2025
24 companies · $819 in 2025
The $819 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $106 · 2021: $416 · 2022: $751 · 2023: $814 · 2024: $894 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,474 · Education: $52.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,474.37 |
| Education | $52.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $635.63 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $450.67 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Aurinia Pharma U.S., INC. | $330.18 | 2022-2025 | Lupkynis |
| Vifor Pharma, INC. | $321.27 | 2019-2024 | Veltassa |
| Travere Therapeutics, INC. | $272.07 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $267.61 | 2022-2025 | Terlivaz, Acthar |
| Astrazeneca Pharmaceuticals LP | $244.13 | 2019-2024 | Lokelma, Farxiga |
| Novartis Pharmaceuticals Corporation | $232.57 | 2023-2025 | |
| Glaxosmithkline, LLC. | $219.14 | 2019-2023 | Jesduvroq, Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $203.17 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $198.40 | 2022-2025 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $170.02 | 2019 | |
| Fresenius USA Marketing, INC. | $127.92 | 2019-2025 | Velphoro, Velphoro |
| Opko Pharmaceuticals, LLC | $110.27 | 2019-2022 | |
| Akebia Therapeutics INC | $96.33 | 2022-2024 | Auryxia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $83.61 | 2020-2025 | Ultomiris |
| Daiichi Sankyo INC. | $75.73 | 2019-2024 | Injectafer |
| Ardelyx, INC. | $74.34 | 2024 | Ibsrela |
| Lilly USA, LLC | $60.38 | 2024 | Jardiance |
| Apellis Pharmaceuticals, INC. | $53.97 | 2025 | Empaveli |
| Scpharmaceuticals INC. | $48.73 | 2025 | |
| Ani Pharmaceuticals, INC. | $47.11 | 2022-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $41.43 | 2020-2021 | |
| Horizon Therapeutics Plc | $22.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.